1. From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized Trial
Ann Intern Med. 2008;148(8): doi: /
Figure Legend:
Reproduced with permission from Acta Obstet Gynecol Scand Suppl. 1977;64:1-91.
Date of download: 11/14/2017
Copyright © American College of Physicians. All rights reserved.

2. From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized Trial
Ann Intern Med. 2008;148(8): doi: /
Figure Legend:
CIN 1 = cervical intraepithelial neoplasia (mild); ITT = intention-to-treat. *Dyspareunia. †More than 3 satisfactory sexual events per month at baseline.
Date of download: 11/14/2017
Copyright © American College of Physicians. All rights reserved.

3. From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized Trial
Ann Intern Med. 2008;148(8): doi: /
Figure Legend:
*Least-squares means from negative binomial model of mean satisfactory sexual events during treatment, adjusted for baseline satisfactory sexual event and site.
Date of download: 11/14/2017
Copyright © American College of Physicians. All rights reserved.

4. From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized Trial
Ann Intern Med. 2008;148(8): doi: /
Figure Legend:
*Estimates from negative binomial model of mean sexual satisfactory events during treatment, adjusted for baseline sexual satisfactory events, site, age, and body mass index.
Date of download: 11/14/2017
Copyright © American College of Physicians. All rights reserved.

5. From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized Trial
Ann Intern Med. 2008;148(8): doi: /
Figure Legend:
The testosterone levels at baseline exceed the levels used as an inclusion criterion (<3.8 pmol/L [<1 pg/mL]) because the authors used a different, more sensitive testosterone assay than that used to screen women for eligibility.
Date of download: 11/14/2017
Copyright © American College of Physicians. All rights reserved.